Review says spontaneous regression of equine sarcoids is rare: full analysis

A new review in Equine Veterinary Journal is pushing back on a familiar assumption in equine practice: that sarcoids sometimes just go away on their own. Author Sabine Brandt concludes that spontaneous regression of equine sarcoids is an exceptional event, not a typical feature of the disease, and that the small number of likely true regressions appears confined to mild occult lesions and possibly some mild verrucous lesions. (researchgate.net)

That matters because sarcoids remain one of the most important dermatologic and oncologic problems in horses. They’re benign in the metastatic sense, but locally aggressive, often persistent, and linked primarily to bovine papillomavirus types 1 and 2. Depending on the source, sarcoids account for a substantial share of equine skin tumors and neoplasms overall, and lesion behavior can vary widely by type and location. Common sites include the head, ventral abdomen, thorax, and paragenital region, with trauma and wound sites often implicated in development. (researchgate.net)

Brandt’s review revisits the evidence behind reported spontaneous resolution and finds the literature thinner than many clinicians may assume. One of the central problems is case definition: in the older reports, diagnosis was usually based on clinical appearance alone, without histopathology, and often without PCR-based confirmation of BPV1/2. The review argues that this leaves open a basic question — whether some lesions labeled as sarcoids were actually something else. That diagnostic uncertainty is especially important in a disease where biopsy can itself be approached cautiously because of concern over lesion aggravation. (researchgate.net)

The paper also places regression in a biologic context. In cattle, BPV-induced fibropapillomas usually regress spontaneously after several months, but equine sarcoids behave differently, likely because viral immune evasion and host factors support persistence. Brandt notes that while a few mild lesions may break that pattern, the overall picture still supports sarcoids as chronic lesions rather than self-limiting ones. That interpretation is consistent with prior work on the immune microenvironment of sarcoids and with a broader 2023 review of sarcoid immunotherapy, which described impaired immune responses and ongoing efforts to develop more effective immune-based treatment strategies. (researchgate.net)

The review lands against a backdrop of persistent uncertainty about treatment efficacy. A 2024 systematic review of equine sarcoid treatments found only 10 studies suitable for inclusion, with overall risk of bias ranging from “some concerns” to “critical,” wide variation in reported regression rates, and insufficient evidence to recommend one treatment over another. In other words, the field is already working with limited comparative evidence. If spontaneous regression is overestimated, that could distort both clinical expectations and interpretation of uncontrolled case series. (abvp.com)

For veterinary professionals, the practical message is less about abandoning conservative management in every case and more about being precise. Lesion type matters. Location matters. Diagnostic confidence matters. And counseling matters, too: pet parents may hear anecdotes about sarcoids disappearing, but this review suggests those stories shouldn’t be generalized across lesion types or used to justify delay in cases with more aggressive features. That aligns with guidance from referral and reference sources that warn inappropriate treatment, or in some cases poorly chosen intervention, can worsen disease behavior or complicate future management. (researchgate.net)

One notable sign of interest in the paper is that commentary has already begun to appear in the academic literature, including a recent item titled “Comments on ‘Spontaneous regression of equine sarcoids is an exceptional event.’” While that record alone doesn’t establish the substance of the response, it suggests the review is already prompting discussion. (biblio.ugent.be)

Why it matters: In a disease where treatment studies are hard to compare, recurrence is common, and management decisions often balance cost, location, welfare, and cosmetic outcome, even a small misconception about natural history can have outsized effects. This review reinforces that spontaneous regression should be treated as the exception, not the baseline expectation, especially when clinicians are weighing whether to monitor, intervene, or assess treatment success over time. (researchgate.net)

What to watch: The next step for the field is better phenotyped, controlled sarcoid research, ideally with stronger lesion confirmation and follow-up, so clinicians can separate true spontaneous resolution from misclassification and get cleaner evidence on which therapies actually change outcomes. (researchgate.net)